Adaptimmune Therapeutics (ADAP) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key achievements and product updates

• Achieved first FDA approval for engineered T-cell therapy in a solid tumor (Tecelra for synovial sarcoma) in 2023, marking a major milestone in cell therapy for solid tumors.

• Lete-cel pivotal trial data presented in late 2023; rolling BLA submission planned for 2025, targeting both synovial sarcoma and myxoid round cell liposarcoma.

• Combined peak sales for Tecelra and lete-cel in the U.S. launch indications estimated at $400 million, with cash flow break-even targeted by 2027.

• Manufacturing and commercial infrastructure established, with 11 authorized treatment centers operational and plans to expand to 30 by end of 2025.

• Over 70% payer coverage achieved for Tecelra, with strong support from NCCN guidelines and rapid treatment center onboarding.

Clinical and commercial strategy

• Tecelra offers a transformative alternative for advanced synovial sarcoma, showing a 43% response rate and durable responses in pivotal trials.

• Lete-cel demonstrated a 42% response rate and 12-month median duration of response in pivotal trials, with breakthrough designation for both target indications.

• Commercial synergies between Tecelra and lete-cel allow for efficient scaling and rapid launch of new products using the same network.

• Expansion opportunities include sequential use, new HLA targets, and global markets, potentially increasing the eligible patient pool to 9,000.

• Patient support and logistics programs in place to facilitate access and streamline the treatment process.

Pipeline and future directions

• Partnership with Galapagos to develop uza-cel for head and neck cancer, leveraging distributed manufacturing for faster delivery.

• Preclinical programs targeting PRAME and CD70, with IND filings planned for 2025 and 2026, respectively; PRAME program could address up to 29,000 patients.

• Long-term vision includes expanding cell therapy to other solid tumors and leveraging high-sensitivity TCRs for broader indications.

• Allogeneic and in vivo cell therapy platforms identified as promising future modalities, though autologous therapies expected to dominate the next decade.

• Ongoing focus on specialization and tailored delivery, rather than scale, to address unique challenges in cell therapy commercialization.